Narrow search
Showing 1 - 10 of 1,764
Cover Image
Ensuring Appropriate Care in Epilepsy: An Overview of Epidemiological and Cost of Illness Considerations
Heaney, Dominic C.; Sander, Josemir W.A.S. - In: Disease Management and Health Outcomes 4 (1998) 6, pp. 303-313
Epilepsy is an important health problem throughout the world. In order to best manage epilepsy within a population, its … burden on health services and society as a whole. The average annual cost of epilepsy may be as high as $US14 500 (1995 … essential part of raising the awareness of this significant public health problem. Many important issues regarding the …
Persistent link: https://www.econbiz.de/10005243022
Cover Image
Under-Utilisation of beta-Blockers After Acute Myocardial Infarction: Pharmacoeconomic Implications
Bradford, W. David; Chen, Jersey; Krumholz, Harlan M. - In: PharmacoEconomics 15 (1999) 3, pp. 257-268
mortality associated with under-use 2. increased demand for related medical resources when the health state following an AMI is …
Persistent link: https://www.econbiz.de/10005243162
Cover Image
Contribution of Pharmaceutical Innovation to Longevity Growth in Germany and France, 2001-7
Lichtenberg, Frank R. - In: PharmacoEconomics 30 (2012) 3, pp. 197-211
This paper investigates the contribution of pharmaceutical innovation to recent longevity growth in Germany and France. The effect of the vintage of prescription drugs (and other variables) on the life expectancy and age-adjusted mortality rates of residents of Germany is examined, using...
Persistent link: https://www.econbiz.de/10009493381
Cover Image
National Patterns of Risk-Standardized Mortality and Readmission for Acute Myocardial Infarction and Heart Failure.
Bernheim, Susannah; Grady, Jacqueline; Lin, Zhenqiu; … - Mathematica Policy Research - 2010
This article provides a national perspective on hospital performance for 30-day risk-standardized mortality rates and risk-standardized readmission rates for patients hospitalized with acute myocardial infarction and heart failure.
Persistent link: https://www.econbiz.de/10010608790
Cover Image
Years of Potential Life Lost and Indirect Costs of Melanoma and Non-Melanoma Skin Cancer: A Systematic Review of the Literature
GuyJr, Gery P. Guy; Ekwueme, Donatus U. - In: PharmacoEconomics 29 (2011) 10, pp. 863-874
Skin cancer is the most common form of cancer in the US, and an important public health concern both in the US and …
Persistent link: https://www.econbiz.de/10010614404
Cover Image
Simvastatin After Orthotopic Heart Transplantation: Costs and Consequences
Krobot, Karl J.; Wenke, Klaus; Reichart, Bruno - In: PharmacoEconomics 15 (1999) 3, pp. 279-289
setting: The perspective of the economic analysis was that of the German health insurance fund. Life-years gained were …
Persistent link: https://www.econbiz.de/10005449010
Cover Image
Counting the Costs of Drug-Related Adverse Events
White, T. Jeffrey; Arakelian, Annet; Rho, Jay P. - In: PharmacoEconomics 15 (1999) 5, pp. 445-458
Adverse drug events occur frequently and lead to a significant number of fatalities each year. It has been estimated that fatalities directly attributable to adverse drug reactions are the fourth to sixth leading cause of death in US hospitals, exceeding deaths caused by pneumonia and diabetes....
Persistent link: https://www.econbiz.de/10005449050
Cover Image
Cost-Effectiveness Analysis of Ramipril in Heart Failure after Myocardial Infarction: Economic Evaluation of the Acute Infarction Ramipril Efficacy (AIRE) Study for Germany from th...
Schadlich, Peter K.; Huppertz, Eduard; Brecht, Josef Georg - In: PharmacoEconomics 14 (1998) 6, pp. 653-669
-effectiveness analysis was conducted from the perspective of the Statutory Health Insurance (SHI) provider in Germany. A modelling approach …
Persistent link: https://www.econbiz.de/10005449120
Cover Image
Cost Effectiveness of Letrozole in the Treatment of Advanced Breast Cancer in Postmenopausal Women in the UK
Nuijten, Mark; Meester, Liebeth; Waibel, Franz; Wait, … - In: PharmacoEconomics 16 (1999) 4, pp. 379-397
Objective: To simulate the treatment of postmenopausal women with advanced breast cancer from second-line hormone therapy to death, and to generate estimates of the cost and effectiveness of letrozole and megestrol in order to determine the incremental cost effectiveness of letrozole, expressed...
Persistent link: https://www.econbiz.de/10005449176
Cover Image
Cost Analysis of Palliative Care for Terminally Ill Cancer Patients in the UK After Switching from Weak to Strong Opioids
Guest, Julian F.; Hart, Warren M.; Cookson, Ronald F. - In: PharmacoEconomics 14 (1998) 3, pp. 285-297
-thirds of the expected total cost was incurred by the UK National Health Service (NHS), with the remainder incurred by voluntary …
Persistent link: https://www.econbiz.de/10005449313